HomeCompareNNMX vs CL

NNMX vs CL: Dividend Comparison 2026

NNMX yields 1000000.00% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NNMX wins by $4.7683925249533696e+36M in total portfolio value
10 years
NNMX
NNMX
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full NNMX calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — NNMX vs CL

📍 NNMX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNNMXCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NNMX + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NNMX pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NNMX
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, NNMX beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NNMX + CL for your $10,000?

NNMX: 50%CL: 50%
100% CL50/50100% NNMX
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

NNMX
No analyst data
Altman Z
-202.4
Piotroski
1/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NNMX buys
0
CL buys
0
No recent congressional trades found for NNMX or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNNMXCL
Forward yield1000000.00%2.43%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$4.7683925249533696e+36M$40.8K
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$5,401.96
Total dividends collected$4.7683311610149396e+36M$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: NNMX vs CL ($10,000, DRIP)

YearNNMX PortfolioNNMX Income/yrCL PortfolioCL Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,012$312.01+$100.00MNNMX
2$934,786,450,701$934,679,439,252.34$12,196$412.95+$934786.44MNNMX
3$8,165,787,108,578,292$8,164,786,887,076,042.00$13,599$549.66+$8165787108.56MNNMX
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$15,288$736.64+$66665884190957.63MNNMX
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$17,353$995.28+$508662171058048128.00MNNMX
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$19,926$1,357.80+$3.62723524842849e+21MNNMX
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$23,194$1,873.82+$2.417368115915061e+25MNNMX
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$27,439$2,621.52+$1.5056740286145463e+29MNNMX
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$33,088$3,727.38+$8.764771002818475e+32MNNMX
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$40,806$5,401.96+$4.7683925249533696e+36MNNMX

NNMX vs CL: Complete Analysis 2026

NNMXStock

Boston Therapeutics, Inc. develops, manufactures, and commercializes therapeutic drugs to address unmet medical needs in diabetes and inflammatory diseases. The company develops BTI-320, a non-systemic carbohydrate-based compound tablet that is in Phase II clinical trial for reduction of post-meal blood glucose levels in pre-diabetes patients and type 2 diabetes patients; and IPOXYN, an injectable drug to prevent necrosis, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications. It is also developing BTI-410, a peptide injectable compound, which is in Phase II clinical trial to stimulate beta cell maturation for development as a new insulin producing cell agent for the pancreas in type 2 diabetes patients and type 1 patients who are on immunosuppression therapy after having undergone kidney transplant surgery; SUGARDOWN, a non-systemic polysaccharide based dietary supplement to support healthy blood glucose levels; and OXYFEX, a veterinary medicine application used as an oxygen delivery agent similar to a RBC replacement for ischemia and trauma, as well as for blood loss during surgery. In addition, the company provides automatic retinal image analysis (ARIA), a diagnostic device for screening of cardiovascular risk, such as stroke. Boston Therapeutics, Inc. is headquartered in Lawrence, Massachusetts.

Full NNMX Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this NNMX vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NNMX vs SCHDNNMX vs JEPINNMX vs ONNMX vs KONNMX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.